Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

Main Article Content

Andrew Blauvelt
Lars Iversen
Sandy McBride
Melinda Gooderham
Petra Staubach
Paul Yamauchi
Fabienne Staelens
Veerle Vanoorden
Katy White
Paolo Gisondi

Keywords

bimekizumab, efficacy, psoriasis, BE RADIANT trial

Abstract

N/A

References

1 Glatt S. Ann Rheum Dis 2017;77:523–32;

2 Reich K. N Engl J Med 2021; 385:142–52;

3 Edson-Heredia E. J Invest Dermatol 2014;134:18–23

Most read articles by the same author(s)

<< < 1 2 3 4 5 6